<- Go Home
MedImmune Oncology Inc.
MedImmune Oncology Inc., a pharmaceutical company, engages in the development and commercialization of products for patients with cancer and acquired immune deficiency syndrome. MedImmune Oncology Inc. was formerly known as U.S. Bioscience, Inc. As a result of acquisition of U.S. Bioscience, Inc. by MedImmune, LLC, U.S. Bioscience, Inc. name was changed. The company was founded in 1987 and is based in West Conshohocken, Pennsylvania. As of November 23, 1999, MedImmune Oncology Inc. operates as a subsidiary of MedImmune, LLC.
Market Cap
$502.1M
Volume
155.8K
Cash and Equivalents
$8.8M
EBITDA
-$10.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$25.7M
Profit Margin
82.07%
52 Week High
$19.00
52 Week Low
$5.94
Dividend
N/A
Price / Book Value
9.61
Price / Earnings
-40.16
Price / Tangible Book Value
9.61
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$11.8M
Return on Equity
25.31%
Return on Assets
-11.92
Cash and Short Term Investments
$20.3M
Debt
$1.3M
Equity
$52.1M
Revenue
$31.3M
Unlevered FCF
-$10.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium